# Adenosine as an Adjunct to Blood Cardioplegia

Study · id `cardio:ct-nct02681913` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02681913](<https://clinicaltrials.gov/study/NCT02681913>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT02681913

Browse, organ or system: Heart  
Browse, condition area: Heart failure  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 100 participants.

## Technical summary

Registry record NCT02681913. Randomized; quadruple masking; primary purpose prevention. Start 2016-02 (registry gives no type); primary completion 2018-07 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose prevention
- Phase: Phase 2
- Enrolled: 100 participants (planned count; ClinicalTrials.gov record NCT02681913, source copy `cardio:ctgov-nct02681913-2017-04-20`, retrieved 2026-10-31)
- Start date: 2016-02 (registry gives no type) (ClinicalTrials.gov record NCT02681913, source copy `cardio:ctgov-nct02681913-2017-04-20`, retrieved 2026-10-31)
- Primary completion: 2018-07 (anticipated) (ClinicalTrials.gov record NCT02681913, source copy `cardio:ctgov-nct02681913-2017-04-20`, retrieved 2026-10-31)
- Completion: 2018-12 (anticipated) (ClinicalTrials.gov record NCT02681913, source copy `cardio:ctgov-nct02681913-2017-04-20`, retrieved 2026-10-31)
- Countries: Netherlands (ClinicalTrials.gov record NCT02681913, source copy `cardio:ctgov-nct02681913-2017-04-20`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02681913-2017-04-20`, retrieved 2026-10-31)

## The registry's words

- Brief title: Adenosine as an Adjunct to Blood Cardioplegia
- Condition: Pathological Processes
- Condition: Cardiomyopathies
- Intervention (Drug): Adenosine
- Lead sponsor: Amphia Hospital
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Cardiomyopathy (heart muscle disease) (`cardio:cardiomyopathy`)
- Registry lists this organization as the lead sponsor: Amphia Hospital (`cardio:org-amphia-hospital`)

## Provenance

Content hash: 1224bc0ae22279f06936543ab0046743c638441c32665f086c3d6c5fa3be19f8
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
